Insmed vs Eli Lilly
Insmed (INSM) and Eli Lilly (LLY) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $31B
- Last close
- $141.33
- 12 months
- −29.2%
- Market value
- $1.27T
- Last close
- $1,347.11
- 12 months
- +29.1%
At a glance
- The biggest part of Insmed's revenue is ARIKAYCE (72%); at Eli Lilly it is Net product revenue (94%).
- Insmed earns 75% of its revenue in the United States, Eli Lilly 67%.
- By market value, Eli Lilly ($1.27T) is about 41 times Insmed ($31.0B).
- Over the last 12 months Insmed's share price moved −29.2% and Eli Lilly's +29.1%; against the S&P 500 that is −34.9 points and +23.4 points.
- In their last fiscal years Insmed kept -210.5% of revenue as net income and Eli Lilly 31.7%.
- In the last 90 days insiders reported 0 open-market purchases at Insmed and 0 at Eli Lilly; members of Congress disclosed 0 trades in Insmed and 4 in Eli Lilly.
- Next results: Insmed Feb 17, 2027, Eli Lilly Feb 2, 2027.
How each one makes money: Insmed revenue · Eli Lilly revenue
Share prices on one chart
Insmed and Eli Lilly, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Insmed INSMNASDAQ · Pharmaceutical Preparations | Eli Lilly LLYNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $31B | $1.27T |
| Revenue, last fiscal year | $606M | $65.2B |
| Net income, last fiscal year | −$1.28B | $20.6B |
| Net marginNet income as a share of revenue | -210.5% | 31.7% |
| Free cash flow | −$968M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Eli Lilly against
Common questions
How is Insmed different from Eli Lilly?
Insmed (INSM) is in Pharmaceutical Preparations on NASDAQ, with $606M of revenue in its last fiscal year and a net margin of -210.5%. Eli Lilly (LLY) is in Pharmaceuticals on NYSE, with $65.2B of revenue in its last fiscal year and a net margin of 31.7%. The biggest part of Insmed's revenue is ARIKAYCE (72%); at Eli Lilly it is Net product revenue (94%). Insmed earns 75% of its revenue in the United States, Eli Lilly 67%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Insmed and Eli Lilly compare in size?
Eli Lilly has the larger market value: Insmed $31B and Eli Lilly $1.27T, at the last close.
Whose share price rose more over the last 12 months, INSM or LLY?
Over the last 12 months Insmed moved −29.2% and Eli Lilly +29.1%. Past price moves say nothing about the future.
Which has had more insider buying, Insmed or Eli Lilly?
Since 2006, Insmed insiders reported 81 open-market purchases against 35 for Eli Lilly. These are counts of what was filed, not a view on either stock.
Do members of Congress trade INSM or LLY?
In the last 12 months, members of Congress disclosed 1 trades in Insmed (INSM) and 27 in Eli Lilly (LLY).
When did insiders last buy INSM and LLY?
Insmed: May 22, 2025. Eli Lilly: Aug 15, 2025.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Insmed pageEli Lilly pageRare insider trades this weekAll comparisons
https://oqro.io/compare/insm-vs-lly







